Biotech · Private company · Boston, MA, US
Verve Therapeutics, Inc.
SEC CIK 0001840574
Track this companyFree. Adds Verve Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials33 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- VERVE-102Phase 2 · AtherosclerosisClinicalTrials.gov · fetched Nov 12, 2026
- VERVE-102Phase 1 · Heterozygous Familial HypercholesterolemiaClinicalTrials.gov · fetched Nov 12, 2026
- VERVE-201Phase 1 · HypercholesterolemiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular DiseasePHASE2 · RECRUITING · started Sep 24, 2026ClinicalTrials.gov NCT07839936 · fetched Nov 12, 2026
- Phase 1b Study of VERVE-201 in Patients With Refractory HyperlipidemiaPHASE1 · RECRUITING · started Oct 30, 2024ClinicalTrials.gov NCT06451770 · fetched Nov 12, 2026
- A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery DiseasePHASE1 · RECRUITING · started Apr 30, 2024ClinicalTrials.gov NCT06164730 · fetched Nov 12, 2026
SEC filings9
- 8-K · 8-KSEC EDGAR · filed Jul 25, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 15, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 17, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 10, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 14, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 14, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 14, 2025 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 27, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 27, 2025 · fetched Nov 12, 2026